Namilumab Biosimilar - Research Grade

Human

CSF2

>1mg/ml

IgG1 - kappa

CHO Cells

Mavrilimumab Biosimilar - Research Grade (ICH5054), Lenzilumab Biosimilar - Research Grade (ICH5166), Gimsilumab Biosimilar - Research Grade (ICH5574), Otilimab Biosimilar - Research Grade (ICH5748), Plonmarlimab Biosimilar - Research Grade (ICH5777)

https://www.imgt.org/mAb-DB/

ICH3002

P04141

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of namilumab, a fully human anti-GM-CSF monoclonal antibody (human IgG1, kappa) that binds the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF, encoded by CSF2; UniProt P04141). It is supplied for research use only and is not the clinical drug; it is not intended for human or veterinary use. Built around the GM-CSF target, it is useful as a well-defined tool for studying GM-CSF neutralization and GM-CSF-driven myeloid biology in vitro. Typical research applications include use as a positive/reference binder in ligand-capture and neutralization assays, as an isotype-matched benchmark for characterizing other anti-GM-CSF reagents, and as a control in cell-based assays of myeloid differentiation and activation. It is offered at research grade with low endotoxin (<1 EU/mg; ultra-low <0.5 EU/mg options), in bulk milligram-to-gram quantities suitable for assay development, screening cascades, and preclinical experimental work. As with all biosimilar tool antibodies, users should validate lot performance in their own assay system. CSF2 encodes granulocyte-macrophage colony-stimulating factor (GM-CSF), a secreted glycoprotein cytokine produced by activated T cells, macrophages, endothelial cells, and fibroblasts. GM-CSF signals through a heterodimeric receptor comprising a ligand-specific alpha chain (CSF2RA) and the shared beta chain (CSF2RB, also used by IL-3 and IL-5), triggering JAK2/STAT5, PI3K, and MAPK pathways. It promotes the survival, proliferation, and differentiation of granulocyte and macrophage progenitors and licenses inflammatory activation of mature myeloid cells, dendritic cells, and tissue macrophages. Beyond hematopoiesis, GM-CSF is a key driver of inflammatory and autoimmune tissue damage, coordinating pathogenic myeloid responses; it is also essential for alveolar macrophage function and pulmonary surfactant clearance. These roles make GM-CSF an important therapeutic and research target in inflammatory disease.

GM-CSF, Colony-stimulating factor, CSF, Molgramostin, Sargramostim, Granulocyte-macrophage colony-stimulating factor

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks